Cargando…

Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade

Mucosal melanoma is a rare form of melanoma which arises from melanocytes in the mucosal membranes and can be effectively treated with immune checkpoint blockade (ICB). However, response rates in mucosal melanoma are lower than those observed for cutaneous melanomas. Targeted sequencing of up to 447...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buchbinder, Elizabeth I., Weirather, Jason L., Manos, Michael, Quattrochi, Brian J., Sholl, Lynette M., Brennick, Ryan C., Bowling, Peter, Bailey, Nancy, Magarace, Lisa, Ott, Patrick A., Haq, Rizwan, Izar, Benjamin, Giobbie‐Hurder, Anita, Hodi, F. Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026918/ https://www.ncbi.nlm.nih.gov/pubmed/33724703 http://dx.doi.org/10.1002/cam4.3789

Ejemplares similares

EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
por: Tabasum, Saba, et al.
Publicado: (2023)

Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial
por: Ott, Patrick A, et al.
Publicado: (2021)

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis
por: Mooradian, Meghan J, et al.
Publicado: (2020)

Su1188 ABDOMINAL CT SHOULD NOT BE USED TO SCREEN FOR IMMUNE CHECKPOINT INHIBITOR COLITIS
por: Braschi-Amirfarzan, Marta, et al.
Publicado: (2020)

Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
por: Li, Xiaoyu, et al.
Publicado: (2023)

Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
por: Buchbinder, Elizabeth I., et al.
Publicado: (2023)

Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS
por: Grover, Shilpa, et al.
Publicado: (2020)

A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma
por: Ibrahim, Nageatte, et al.
Publicado: (2016)

OR19-5 The Impact Of High Dose Glucocorticoids On The Outcome Of Immune Checkpoint Inhibitor-related Thyroid Disorders And The Baseline TSH As A Predictive Biomarker
por: Min, Le, et al.
Publicado: (2019)

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
por: Rahma, Osama E, et al.
Publicado: (2022)

Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome
por: Nishino, Mizuki, et al.
Publicado: (2014)

Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
por: Elias, Rawad, et al.
Publicado: (2018)

A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade
por: Miller, Peter G., et al.
Publicado: (2020)

The Protein Kinase C Inhibitor Enzastaurin Exhibits Antitumor Activity against Uveal Melanoma
por: Wu, Xinqi, et al.
Publicado: (2012)

The role of IFN-γ-signalling in response to immune checkpoint blockade therapy
por: Wong, Chun Wai, et al.
Publicado: (2023)

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
por: Miao, Diana, et al.
Publicado: (2018)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
por: Subrahmanyam, Priyanka B., et al.
Publicado: (2018)

T-cell response to checkpoint blockade immunotherapies: from fundamental mechanisms to treatment signatures
por: Elliot, Thomas A.E., et al.
Publicado: (2023)

Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma
por: Zukotynski, Katherine, et al.
Publicado: (2014)

Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition
por: Naik, Girish S., et al.
Publicado: (2019)

Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features
por: Schoenfeld, Jonathan D., et al.
Publicado: (2019)

Diffuse large B-cell lymphomas have spatially defined, tumor immune microenvironments revealed by high-parameter imaging
por: Wright, Kyle T., et al.
Publicado: (2023)

Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
por: Duan, Jingjing, et al.
Publicado: (2018)

Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
por: Ott, Patrick A., et al.
Publicado: (2015)

Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know
por: Braschi-Amirfarzan, Marta, et al.
Publicado: (2017)

Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma
por: Zhou, Jun, et al.
Publicado: (2011)

Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?
por: Cha, Edward, et al.
Publicado: (2013)

Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma
por: Wu, Xinqi, et al.
Publicado: (2018)

Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors
por: Rezasoltani, Sama, et al.
Publicado: (2020)

Response to immune checkpoint blockade improved in pre-clinical model of breast cancer after bariatric surgery
por: Sipe, Laura M, et al.
Publicado: (2022)

Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service
por: Abu-Shawer, Osama, et al.
Publicado: (2020)

Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade
por: Natale, Christopher A, et al.
Publicado: (2018)

Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction
por: Wei, Hong, et al.
Publicado: (2019)

Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC
por: Tian, Yaru, et al.
Publicado: (2020)

Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice
por: Küçükköse, Emre, et al.
Publicado: (2022)

Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors
por: Palmer, Adam C., et al.
Publicado: (2022)

Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer
por: Rossetti, Rafaela, et al.
Publicado: (2022)

Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders
por: Zhou, Liye, et al.
Publicado: (2022)

Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade
por: Xu, Lijun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4lsllsq3qsq0m19evkm72qnlnu